Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Member States Want Action Over High-Risk IVDs And Eudamed Medical Device Database

Executive Summary

After some 10 years of the implementation of the EU’s Medical Device and IVD Regulations being an annual agenda item at December Council of the EU meetings, the scale of problems remains the same.

You may also be interested in...



Commission Proposes To Extend IVDR Transition Periods And Launch Eudamed Sooner

Despite protests from the European Commission that it would not extend the IVDR transition periods any further and could not launch the Eudamed database until all modules were ready, these things and more are due to happen, and soon.

Rebooting EU Medtech: Appetite For Urgent Discussions To Address Failing Regulations Grows

Lack of predictability uncertainty over fees and inefficient working practices inherent in the current implementation of EU rules are all demanding a rethink in the EU’s current and future medtech rules. Industry expects discussions to kick off early next year.

MedTech Europe’s Position Paper Aims To Smooth Certification Pathway For High-Risk IVDs

With the deadline for class D high-risk IVDs less than 18 months away and the underpinning regulatory structure still embryonic, MedTech Europe calls for clearer policies to give manufacturers a good chance of overcoming the regulatory challenges in time.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT148486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel